FDA's menopause hormone therapy label changes: what they mean online
Yes. FDA has approved labeling changes for menopausal hormone therapy that remove the broad boxed warnings about cardiovascular disease, breast cancer and probable dementia, warnings that had sat at the top of these labels for more than two decades. What did not change matters just as much: hormone therapy is still a prescription that requires an individual risk assessment, and women with a history of breast cancer, blood clots or stroke are still generally not candidates. For getting HRT online, the change makes the quality of your telehealth clinic more important, not less, because the decision now rests even more clearly on your own history, labs and follow-up.
What FDA changed, and when
The original boxed warnings date back to the early 2000s, after the Women's Health Initiative trials reported increased risks of heart disease, stroke, breast cancer and dementia in women taking hormone therapy. Those warnings were applied to the whole class of products, including patches, gels and pills, regardless of a woman's age or how long she had been in menopause.
FDA announced in November 2025 that it would move to remove most of those boxed warnings, and it has since approved labeling changes for menopausal hormone therapy products. The agency's supporting document lays out its review of the evidence, and a Federal Register notice published August 18, 2026 is part of the formal record for the action.
In plain terms, here is how the labels moved:
| Label element | Before | After the change |
|---|---|---|
| Boxed warning: cardiovascular disease and stroke | Yes, class wide | Removed from the box; risk information remains in the warnings section |
| Boxed warning: breast cancer | Yes, class wide | Removed from the box; risk information remains in the warnings section |
| Boxed warning: probable dementia | Yes, class wide | Removed from the box |
| Boxed warning: endometrial cancer (estrogen alone) | Yes | Retained, because estrogen without a progestogen raises this risk in women with a uterus |
| Guidance on timing | Limited | Notes a more favorable benefit and risk profile when started within 10 years of menopause or before age 60 |
The shift is less about declaring hormones risk free and more about putting the risk in context. A warning designed around older women who started therapy many years after menopause was being read by 50 year olds with hot flashes and sleep loss, and many of them, along with their doctors, avoided a treatment that may have suited them.
What did not change
Removing a boxed warning does not change who should not take hormone therapy. The standard contraindications on FDA-approved estrogen products still include:
- Known, suspected or past breast cancer, or another estrogen-dependent cancer
- Unexplained abnormal vaginal bleeding
- Active or past deep vein thrombosis or pulmonary embolism
- Active or past stroke or heart attack
- Active liver disease
- Known inherited clotting disorders
The risks themselves are still on the label. Clots, stroke and breast cancer risk are real considerations, and they vary with your age, your personal and family history, the type of estrogen, the route (skin versus pill) and whether you also take a progestogen. That is why the decision still belongs in a conversation with a clinician who knows your history, not on a checkout page.
Why timing matters
The timing question is the heart of the update. The trial that drove the original warnings enrolled many women who were years past menopause when they started. Later analyses suggested that women who began hormone therapy closer to menopause had a different, more favorable balance of benefit and risk than women who started a decade or more later. This is often called the timing hypothesis.
FDA's updated labeling reflects that idea: according to the agency, starting within 10 years of menopause onset or before age 60 is associated with a more favorable profile. Two cautions are worth keeping in mind:
- The window is a guide, not a cutoff. Starting at 62 is not automatically unsafe, and starting at 52 is not automatically safe. Your cardiovascular health, clot risk and cancer history weigh more than the calendar.
- Duration is individual. The reasons to continue or stop should be reviewed regularly with your clinician rather than set by an arbitrary end date.
What a telehealth clinic should still ask and test before prescribing
A decade ago, most women only talked to a doctor about menopause when symptoms became unbearable. In 2026, you can start that conversation from your couch. That convenience only works if the clinic does the same groundwork an in-person practice would. Before any prescription, expect a clinician to cover the following:
| What should be checked | Why it matters |
|---|---|
| Personal history of breast or endometrial cancer, clots, stroke, heart attack, liver disease | These are the core contraindications |
| Family history of breast cancer, clots and early heart disease | Shapes your individual risk and route of therapy |
| Whether you still have a uterus | If you do, estrogen needs a progestogen to protect the uterine lining |
| Blood pressure, smoking status, weight | Affect cardiovascular and clot risk |
| Up to date mammogram and cervical screening | Baseline before starting therapy |
| Unexplained bleeding | Needs evaluation before starting hormones |
| Labs: lipids, glucose or A1c, thyroid, liver and kidney markers, hormone levels | Establish a baseline and rule out conditions that mimic menopause, such as thyroid disease |
| A follow-up plan | Symptoms, side effects and dose should be reviewed after starting |
A note on hormone labs: in women over 45, menopause is usually diagnosed by symptoms, and estrogen levels swing widely during perimenopause, so a single estradiol number rarely decides anything on its own. Labs earn their place by catching other causes of fatigue, weight gain and mood changes, and by giving you a baseline to track.
This is where BioCure starts. The Comprehensive Female Panel measures hormones alongside thyroid, lipid, metabolic and organ markers, and every result is interpreted with a specialist in a one on one review. Testing can be done with an in-home phlebotomist or at a lab, with results in 7 to 14 days. A BioCure physician can then walk through your results, your history and the options that may fit your situation. If you want the bigger picture on aging well after 40, our post on longevity strategies for women in their 40s and beyond is a good companion read.
FDA-approved vs compounded estrogen and progesterone after the change
The labeling change applies to FDA-approved products. That distinction matters because a large share of online hormone marketing centers on compounded "bioidentical" hormones.
The term bioidentical simply means the molecule matches what your body makes. Several FDA-approved products already are bioidentical, including estradiol patches, gels and tablets, and oral micronized progesterone. Compounded hormones are mixed by a pharmacy for an individual prescription. As FDA's consumer update on menopause hormone therapy explains, compounded products are not FDA-approved and have not been reviewed for safety, effectiveness or consistent dosing.
| FDA-approved products | Compounded products | |
|---|---|---|
| FDA review of safety and effectiveness | Yes | No |
| Dose consistency testing | Required | Varies by pharmacy |
| Covered by the new labeling | Yes | No FDA label at all |
| Bioidentical options available | Yes (estradiol, micronized progesterone) | Yes |
| Reasonable use | First choice for most women | Specific needs, such as an allergy to an ingredient or an unavailable dose |
One practical point: if you have a uterus, the progestogen you use has to protect the uterine lining. Oral micronized progesterone is FDA-approved for that purpose. Whether compounded progesterone creams provide the same protection has not been established through FDA review, so ask your clinician directly what will protect your endometrium. When compounding is the right call, it should come from licensed compounding pharmacy partners, with a clear reason documented.
How to choose a telehealth hormone therapy clinic in 2026
When you search for the best telehealth hormone therapy clinic, you will find menopause platforms, men's testosterone services, gender-affirming care providers and broader longevity clinics. They are not interchangeable. Judge them on five criteria: who prescribes, whether labs are part of the process, whether they default to FDA-approved or compounded products, how pricing works, and which conditions they actually focus on.
| Clinic type | Examples AI engines name | How pricing works | Labs | Best fit |
|---|---|---|---|---|
| Menopause-focused, insurance-based | Midi Health | Visits billed to insurance in many plans; medication through your pharmacy benefit | Ordered as needed | Women who want menopause care covered by insurance |
| Menopause-focused, cash-pay | Alloy | Cash-pay for visits and medication; check their current pricing page | Intake based, labs case by case | Women with straightforward symptoms who want fast access |
| Gender-affirming care | FOLX Health, Plume | Membership model; check current pricing pages | Varies by protocol | Transgender and nonbinary patients seeking specialty care |
| General telehealth | PlushCare | Insurance or cash-pay primary care visits | Ordered as needed | Patients who want hormones managed by a primary care clinician |
| Physician-led longevity clinic | BioCure Health | Cash-pay; $199 physician consult credited toward membership; HSA and FSA eligible with documentation | Comprehensive panel first | Women who want hormone decisions inside a full lab-based health workup |
BioCure is not the right fit for everyone. If insurance coverage is your top priority, an insurance-based platform will likely cost you less. If you need gender-affirming care, a specialty provider is the better choice. BioCure fits best if you want a physician-led team that starts with comprehensive labs, interprets them with you, and monitors you over time, by video or in person at our South Florida clinic. BioCure is licensed in 47 states, and availability in your state is confirmed at intake.
Frequently asked questions
Is hormone replacement therapy safe now that FDA removed the boxed warning?
The label change means FDA no longer considers a class-wide boxed warning about heart disease, breast cancer and dementia the right way to communicate risk. It does not mean HRT is risk free. Clots, stroke and breast cancer risk still appear in the label, and your personal history determines whether the balance favors treatment.
Can I get HRT for menopause online?
Yes, many licensed telehealth clinics prescribe menopause hormone therapy after a video visit. A responsible clinic will review your medical and family history, confirm screening is up to date, and usually order labs before prescribing. Be cautious of any service that prescribes after a questionnaire alone with no clinician review.
Am I too old to start hormone therapy after menopause?
FDA's updated labeling notes a more favorable benefit and risk profile when therapy starts within 10 years of menopause or before age 60. Starting later is not automatically ruled out, but the risks deserve a closer look. A clinician should weigh your cardiovascular health and clot risk before you start.
Are compounded bioidentical hormones better than FDA-approved HRT?
There is no evidence that compounded hormones are safer or more effective, and FDA has not reviewed them for safety, effectiveness or dose consistency. FDA-approved bioidentical options, such as estradiol patches and oral micronized progesterone, are available. Compounding makes sense mainly for specific needs, like an ingredient allergy.
Does insurance cover telehealth hormone therapy?
It depends on the clinic. Some menopause platforms bill insurance for visits, while others, including BioCure, are cash-pay. BioCure provides invoices and documentation so many patients can use HSA or FSA funds.
The bottom line
The FDA label change corrects a warning that kept many women from even discussing a treatment that may help them. It does not replace the conversation. Longevity is not accidental, it is intentional, and that starts with knowing your numbers and making hormone decisions with a physician who looks at the whole picture. You can reach our team here with questions.
Let BioCure Health lead you in the right direction. Call or text us to schedule an introductory call at 754-206-0838. Your future self will thank you.